Scientists Reversed 'Permanent' Aging Damage in Human Tissue. Here's What Was Fixed.
BiohackingOne of the oldest assumptions in aging research has been that advanced glycation end products — molecular cross-links that accumulate with age and stiffen arteries, cloud lenses, and harden skin — simply can’t be undone. A new study in Nature Communications just showed that assumption is wrong.
What Happened
Researchers from Revel Pharmaceuticals, Calico, and the University of Colorado Anschutz Medical Campus developed CMLase — an engineered enzyme capable of breaking down a specific glycation marker called Nε-carboxymethyl-lysine (CML). CML is one of the most common advanced glycation end products (AGEs) that accumulate in long-lived proteins throughout the body, particularly in arteries, skin, and eye lenses.
The team screened approximately 45,000 protein structures and then ran five rounds of directed evolution across more than 500 million variants to arrive at a functional enzyme. They then tested CMLase on excised human tissues:
- Arterial tissue from a 75-year-old donor: >70% CML reduction
- Elderly skin samples: >55% CML reduction
- Lens proteins from a 64-year-old donor: 45–78% CML reduction (depending on analytical method)
These are laboratory results on excised tissue, not clinical trials in living patients. The gap between lab demonstration and therapeutic application is significant. But the demonstration itself changes the framing.
Why It Matters
AGEs represent one of the oldest and most intractable mechanisms in biological aging. They accumulate as sugars chemically react with proteins over time — a process that can’t be meaningfully slowed through lifestyle interventions once it’s underway. Arterial stiffness driven by AGE cross-links is a primary contributor to cardiovascular risk with age. Lens clouding leads to cataracts. Skin stiffening is visible aging.
The paradigm in aging research has largely divided into two camps: prevention (slow down the damage accumulation rate) and repair (reverse damage that’s already accumulated). Prevention-focused approaches — caloric restriction, NAD+ supplementation, senolytics — have dominated because repair seemed mechanistically impossible for AGEs specifically.
CMLase shifts that calculus. If an engineered enzyme can remove CML modifications from aged tissue in controlled conditions, the field of repair-based longevity therapeutics becomes more credible. It doesn’t validate any existing supplement stack, and it’s not close to a human treatment. But it establishes the enzymatic reversibility of a marker that was considered permanent.
The So What
The significance of this research isn’t a new supplement or protocol — it’s a proof of concept that changes what “aging repair” means as a research category. The same directed evolution approach used to create CMLase can, in principle, be applied to other AGE crosslinks and other accumulated molecular damage. Revel Pharmaceuticals is building a therapeutic pipeline around this premise.
For practitioners tracking the longevity science landscape, this is the kind of upstream finding that takes 5–10 years to reach clinical application but fundamentally alters the target map. Prevention remains the actionable lever today; enzymatic repair is becoming a credible future one.
Source: Longevity.Technology
Content created with AI assistance and reviewed for accuracy.
Join the conversation
Stack Insiders is our free community for readers who want to go deeper — share resources, ask questions, and connect with others across every vertical we cover.
Join Stack Insiders →